Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 5/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25962907 | 1.00 | CASP2 (0.53) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL16221915 | 0.98 | CASP2 (0.56) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL24483387 | 0.98 | CASP2 (0.56) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL24155207 | 0.98 | CASP2 (0.56) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL15759326 | 0.98 | CASP2 (0.56) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL20255020 | 0.97 | CASP2 (0.54) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL23839867 | 0.96 | CASP2 (0.53) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL23849342 | 0.96 | CASP2 (0.53) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL20254831 | 0.96 | CASP2 (0.53) | CASP2FAAHNAAANOD1DNM1 | |
| SCHEMBL16174166 | 0.91 | CASP2 (0.56) | CASP2FAAHNAAANOD1SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023066236-A1 | AGT INHIBITOR AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2023-04-27 | — | — | WO | disclosed |
| EP-3992291-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| EP-3862362-A2 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3845547-A1 | GALNAC3 CONJUGATED MODIFIED OLIGONUCLEOTIDE FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3828275-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3757215-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3137091-B1 | CONJUGATES OF MODIFIED ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3690049-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3633039-A1 | COMPOSITIONS AND METHODS | Ionis Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| WO-2015042447-A1 | TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2014205451-A2 | COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014179626-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179629-A2 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179620-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |